http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2464576-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d78d7b5f1eae1d6c5aaf3a2efd8db15b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_390ef3f822fbc49a3c0bc2c21e5d1a71 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2011-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0d38b0aba5a8aba913cac8565b1655f |
| publicationDate | 2012-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2464576-C1 |
| titleOfInvention | Method of determining clinical effectiveness in cervical cancer |
| abstract | FIELD: medicine. n SUBSTANCE: one week after the termination of polychemotherapy, daily urine is examined for the amount of cortisol and cortisone, while blood is examined for adrenocorticotropic hormone. It is followed by calculating the relation of total cortisol and cortisone to adrenocorticotropic hormone. If the derived value is 0.74 and higher, high responsiveness to chemopreparations is stated. n EFFECT: use of the method enables selecting the most adequate complex of anticancer chemopreparations for each patient, performing a surgical intervention in more conservative extent. n 1 ex |
| priorityDate | 2011-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.